Risk Factors for Delayed Elimination of Methotrexate in Children, Adolescents and Young Adults With Osteosarcoma

被引：8
作者：
Misaka, Ko [1 ,2 ]
Suga, Yukio [1 ,2 ]
Staub, Yukiko [1 ,2 ]
Tsubata, Atsumi [1 ]
Shimada, Tsutomu [2 ]
Sai, Yoshimichi [2 ]
Matsushita, Ryo [1 ]
机构：
[1] Kanazawa Univ, Fac Pharm, Inst Med Pharmaceut & Hlth Sci, Dept Clin Pharm & Healthcare Sci, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan
[2] Kanazawa Univ, Univ Hosp, Dept Hosp Pharm, Kanazawa, Ishikawa, Japan
来源：
IN VIVO | 2020年 / 34卷 / 06期
关键词：
High-dose methotrexate; osteosarcoma; risk factor; HIGH-DOSE METHOTREXATE; POPULATION PHARMACOKINETICS; CHEMOTHERAPY; SURVEILLANCE; PARAMETERS; CLEARANCE; SURVIVAL; THERAPY; SARCOMA;
D O I：
10.21873/invivo.12185
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Background/Aim: High-dose methotrexate (HD-MTX) is pivotal chemotherapy in the treatment of patients with osteosarcoma. Blood concentrations of MTX are associated with several side effects, but there are large individual differences in the elimination of MTX. The aim of this study was to explore risk factors for delayed elimination of MTX in children, adolescents and young adults with osteosarcoma. Patients and Methods: We conducted a retrospective study on Japanese patients with osteosarcoma who were treated with HD-MTX at Kanazawa University Hospital from April 2006 to March 2015. Risk factors for delayed elimination of methotrexate were identified by multiple logistic regression analysis. Results: A total of 92 cycles of HD-MTX therapy were analyzed. Female and lower creatinine clearance (CCr) were identified as independent risk factors for delayed elimination of MTX. Conclusion: Knowing the factors associated with delayed elimination of MTX could lead to safer and optimized chemotherapy for patients with osteosarcoma.
引用
收藏
页码：3459 / 3465
页数：7
相关论文
共 27 条
[1]   Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand? [J].
Anninga, Jakob K. ;
Gelderblom, Hans ;
Fiocco, Marta ;
Kroep, Judith R. ;
Taminiau, Anstoni H. M. ;
Hogendoorn, Pancras C. W. ;
Egeler, R. Maarten .
EUROPEAN JOURNAL OF CANCER, 2011, 47 (16) :2431-2445
[2]   Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma [J].
Bernthal, Nicholas M. ;
Federman, Noah ;
Eilber, Frederick R. ;
Nelson, Scott D. ;
Eckardt, Jeffrey J. ;
Eilber, Fritz C. ;
Tap, William D. .
CANCER, 2012, 118 (23) :5888-5893
[3]   High dose methotrexate in adult patients with osteosarcoma: Clinical and pharmacokinetic results [J].
Comandone, A ;
Passera, R ;
Boglione, A ;
Tagin, V ;
Ferrar, S ;
Cattel, L .
ACTA ONCOLOGICA, 2005, 44 (04) :406-411
[4]   High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma [J].
Crews, KR ;
Liu, T ;
Rodriguez-Galindo, C ;
Tan, M ;
Meyer, WH ;
Panetta, JC ;
Link, MP ;
Daw, NC .
CANCER, 2004, 100 (08) :1724-1733
[5]   THE EFFECT OF PRIOR CISPLATIN THERAPY ON THE PHARMACOKINETICS OF HIGH-DOSE METHOTREXATE [J].
CROM, WR ;
PRATT, CB ;
GREEN, AA ;
CHAMPION, JE ;
CROM, DB ;
STEWART, CF ;
EVANS, WE .
JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (06) :655-661
[6]   Long-term results in children with standard risk acute lymphoblastic leukaemia treated with 5.0 g/m 2 versus 3.0 g/m 2 methotrexate i.v. according to the modified ALL-BFM 90 protocol. the report of Polish paediatric Leukemia/lymphoma study group [J].
Derwich K. ;
Wachowiak J. ;
Zając-Spychała O. ;
Balcerska A. ;
Balwierz W. ;
Chybicka A. ;
Kowalczyk J.R. ;
Matysiak M. ;
Jackowska T. ;
Sońta-Jakimczyk D. ;
Szczepański T. ;
Wysocki M. .
memo - Magazine of European Medical Oncology, 2011, 4 (3) :184-189
[7]   High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy [J].
Dupuis, Charlotte ;
Mercier, Cedric ;
Yang, Chenguang ;
Monjanel-Mouterde, Suzanne ;
Ciccolini, Joseph ;
Fanciullino, Raphaelle ;
Pourroy, Bertrand ;
Deville, Jean-Laurent ;
Duffaud, Florence ;
Bagarry-Liegey, Danielle ;
Durand, Alain ;
IIiadis, Athanassios ;
Favre, Roger .
ANTI-CANCER DRUGS, 2008, 19 (03) :267-273
[8]  
EVANS WE, 1978, CLIN PHARMACOL THER, V23, P68
[9]   Pharmacokinetic Individualization of High-Dose Methotrexate Chemotherapy for the Treatment of Localized Osteosarcoma [J].
Fujita, Y. ;
Nakamura, T. ;
Aomori, T. ;
Nishiba, H. ;
Shinozaki, T. ;
Yanagawa, T. ;
Takagishi, K. ;
Watanabe, H. ;
Okada, Y. ;
Nakamura, K. ;
Horiuchi, R. ;
Yamamoto, K. .
JOURNAL OF CHEMOTHERAPY, 2010, 22 (03) :186-190
[10]   Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data [J].
Fukuhara, K. ;
Ikawa, K. ;
Morikawa, N. ;
Kumagai, K. .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2008, 33 (06) :677-684
123